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ABSTRACT
Fourty-seven patients with histologically proven grade III-IV astrocytoma received postoperative
accelerated radiotherapy with 2 fractions of 2,65 Gy twice daily, up to total tumor dose of 53 Gy in ten
days. The tolerance of the treatment was good, actuarial survival rates at 2,3 and 5 years were 15%,
9% and 0% respectively.
INTRODUCTION
High grade astrocytomas account for 40% of
all central nervous system malignancies in
adults (Choi et aI., 1970). The surgical
intervention in these highly malignant lesions is
unlikely to be curative, and because of their
lesions' diffused spread continues to be
unsatisfactory. Postoperative irradiation may
increase survival by as much as 100%, but the
prognosis of anaplastic astrocytomas is still one
of the most serious problems in oncology (Leibel
et ai, 1994).
The objective of this study is to evaluate the
efficacy of postoperative Twice Daily
Accelerated Irradiation (TDAI) of patients with
grade III and IV astrocytomas.
MATERIAL AND METHODES
The population for the study was derived
from neurosurgical centers which referred
patients to the Maria Sktodowska-Curie
Memorial Center in Krakow for radiation
therapy. Surgery consisted of as complete
tumor removal as possible. All surgical
specimens were evaluated by the same
pathologist, according to the classification, as
described by Kernohan (Kernohan-Sayre,
1952). Grade III astrocytomas have malignant
cytologic feature, including mitoses and
hyperchromatic nuclei, and in the grade IV
neoplasms, there are significant amounts of
necrosis hemorrhage and marked variation iii
cell size and detail. Between 1989 and 1993,47
adult patients with a histologically confirmed
diagnosis of astrocytoma grade III-IV, received
postoperative TDAI. Patients were treated with
2,65 Gy per fraction, twice daily with a 6 hour
interval between fractions up to the total dose of
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53 Gy over 12 days. The targed volume (based
on pre- and postoperative CT scans)
encompassed the known tumour-bearing area
plus three centimeters of surrounding tissue.
The distribution of patient characteristics is
given in Table I.
Table I. Patient characteristics.





40 and less 19 (40%)







Total resection 9 (19%)
Partial resection 38 (81%)
Histology:
Astrocytoma III 14 (30%)
Astrocytoma IV 33 (70%)
Karnofsky's index:
60% and more 28 (60%)
Less than 60% 19 (40%)
SUPPORTIVE TREATMENT
Systemic anticonvulsants (phenytoin or
phenobarbital) were administrated to all patients
during irradiation. Dexamethasone was given in
a dose of 12-24 mg/day, only as symptomatic
medication required to control cerebral edema.
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Table II. Actuarial survival of 47 patients with
grade III, IV astrocytomas.
Patients were checked every 4 months after
completion of therapy. Physical and neurological
examination were done, and a CT scan of the
brain at each follow-up visit was obtained.
Anaplastic astrocytoma present a supreme
challenge to local modes of therapy. These
tumours are not curable by currently available
postoperative radiotherapeutic techniques. In an
attempt to improve the therapeutic ratio, non
conventional fractionation schedules have been
proposed in many centers. Different studies
have employed increased fractional dose or
decreased treatment time, both of which lead to
an increased biologically effective dose, but
have failed to demonstrate improved long-term
survival. Table III and IV present the results of
postoperative irradiation of anaplastic
astrocytomas according to different regimens of
fractionation. Optimum parameters of dose,
volume and type of fractionation are not defined
for the treatment of high grade astrocytomas
with external beam radiotherapy, but in spite of
all considerable limitations, radiotherapy
remains the most effective treatment at our
disposal for affecting the course of these
tumors. Postoperative irradiation plays a
palliative role in the management of anaplastic
astrocytomas, so we believe that this treatment
should be of short duration and the fewest side-
effects. Therefore our TDAI regimen is worth
recommendation.
Although there were no radiation related
late toxicities in this study, the late effects of
large incremental fractions on normal brain
tissue can be potentially severe. The true
incidence of brain necrosis in our series is
difficult to determine. The reason for this
difficulty includes short survival of patients with
malignant astrocytomas and, therefore the
insufficient time interval for necrosis to develop.
Necrosis, if it occures, usually does from 6 to 22
months after the completion of radiotherapy









The treatment was generally well tolerated,
signs and symptoms of increassed intracranial
pressure occured in 4 patients. Of the 47
patients treated with TDAI, six showed
improvement in their Karnofsky's performance
status (KPS). This improvement was usually
evident at the beginning of the second week of
irradiation. No change in KPS was observed in
41 patients. The probability of survival of 47
patients treated with TDAI is given in Table II.
The lenght of survival was measured from
the day of surgery and estimates of the survival
were obtained by the product-limit method
(Kaplan-Meier, 1958). At the time of this
analysis 42 of 47 patients were known to have
died.
Table III. Results of postoperative hypofractionated irradiation of anaplastic
astrocytomas. .
Author
(Hercbergs et aI., 1989)
(Marcial-Vega et aI., 1989)
(Tamura et aI., 1989)
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Table IV. Results of postoperative multiple daily fractionated irradiation of
anaplastic astrocytomas.
Author Fraction 2-years 5-years
size survival survival
(cGy)
(Gonzalez et aI., 1994) 200 8%
(Hernandez et aI., 1990) 100 7%
(Keirn et aI., 1987) 160 10%
(Ludgate et aI., 1988) 76 17%
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